Want to see HK:2257 full AI Analyst Report?
2257 Stock Chart & Stats
HK$4.00
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$4.00
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$3.67 - HK$22.78
Previous CloseN/A
Volume54.85K
Average Volume (3M)442.62K
Market Cap
HK$445.82M
Enterprise ValueHK$65.29M
Total Cash (Recent Filing)HK$13.52M
Total Debt (Recent Filing)HK$9.31M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding112,157,135
10 Day Avg. Volume408,789
30 Day Avg. Volume442,620
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-9.39
Price to Sales (P/S)0.00
P/FCF Ratio-10.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$162.00M
Bulls Say, Bears Say
Bulls Say
RNAi Therapeutic Platform FocusA dedicated siRNA and delivery-technology focus is a durable strategic asset: platform R&D can generate multiple program opportunities and licensing pathways, and specialized delivery expertise is a high barrier to entry that supports long-term competitive differentiation in oncology and genetic targets.
Improving Cash Burn TrendSequential reduction in cash burn over two years suggests management has materially improved cost control or program prioritization. A sustained lower burn rate extends runway, reduces near-term refinancing frequency, and materially improves the company’s ability to execute longer-term clinical development plans.
Smaller Net Loss In 2025A materially smaller net loss indicates improving operating efficiency or one-off cost reductions; if sustained, this points to better resource allocation and increases the likelihood that future fundraising will support progression of key programs rather than merely covering escalating losses.
Bears Say
Revenue Fell To Zero In 2025Zero reported revenue in the latest year underscores absence of commercialized products or recurring income, meaning the company must rely on external financing or partnerships for ongoing R&D. This weakens long-term self-sustainability and increases dilution and execution risk.
Negative Shareholder EquityNegative equity is a structural balance-sheet weakness that constrains financing options, complicates creditor negotiations, and raises the likelihood of dilutive capital raises. It reduces financial flexibility needed to fund multi-year clinical programs and heightens refinancing risk.
Consistently Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicate the business is not self-funding development activities. Over a multi-quarter horizon this necessitates frequent external funding, which can delay programs, increase cost of capital, and pressure long-term program continuity.
Sirnaomics Ltd. News
2257 FAQ
What was Sirnaomics Ltd.’s price range in the past 12 months?
Sirnaomics Ltd. lowest stock price was HK$3.67 and its highest was HK$22.78 in the past 12 months.
What is Sirnaomics Ltd.’s market cap?
Sirnaomics Ltd.’s market cap is HK$445.82M.
When is Sirnaomics Ltd.’s upcoming earnings report date?
Sirnaomics Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 13 days.
How were Sirnaomics Ltd.’s earnings last quarter?
Sirnaomics Ltd. released its earnings results on Mar 27, 2026. The company reported -HK$0.881 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.881.
Is Sirnaomics Ltd. overvalued?
According to Wall Street analysts Sirnaomics Ltd.’s price is currently Overvalued.
Does Sirnaomics Ltd. pay dividends?
Sirnaomics Ltd. does not currently pay dividends.
What is Sirnaomics Ltd.’s EPS estimate?
Sirnaomics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sirnaomics Ltd. have?
Sirnaomics Ltd. has 112,157,135 shares outstanding.
What happened to Sirnaomics Ltd.’s price movement after its last earnings report?
Sirnaomics Ltd. reported an EPS of -HK$0.881 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.516%.
Which hedge fund is a major shareholder of Sirnaomics Ltd.?
Currently, no hedge funds are holding shares in HK:2257
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sirnaomics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
207.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.12%
Trailing 12-Months
Company Description
Sirnaomics Ltd.
Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing significant medical needs across the United States and the People's Republic of China. Its leading pipeline assets include STP705, which is being investigated for conditions such as cutaneous squamous cell carcinoma in situ, basal cell carcinoma, various liver-related cancers (cholangiocarcinoma, hepatocellular carcinoma, liver metastases), as well as for keloid scar remodeling, hypertrophic scarring, and fat sculpting. Another prominent candidate, STP707, is designed to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, metastatic cutaneous squamous cell carcinoma, non-small cell lung cancer, and both liver and lung fibrosis. Beyond these lead programs, Sirnaomics is advancing STP355 for a range of cancers; STP369 for head and neck/bladder cancers; STP779 for liver, lung, and pancreatic cancers; and STP902 for breast cancer. The company's portfolio also extends to infectious diseases with STP702 for influenza, STP908 for COVID-19, the RIM730 COVID-19 vaccine, and STP909 for HPV/cervical cancer. Furthermore, its developmental pipeline encompasses STP122G for thrombotic disorders, STP125G for hypertriglyceridemia, STP144G for complement-mediated ailments, STP133G for cardiometabolic conditions, and STP155G for hepatitis B virus.
Technical Analysis
Alphamab Oncology
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Transcenta Holding Limited
―
Ascentage Pharma Group International
―